Benzinga | Jul 21, 2021 04:38PM EDT

Alector To Present New Data From Frontotemporal Dementia And Alzheimer's Disease Programs At The 2021 Alzheimer's Association International Conference

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN

Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer's Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado.

Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Alector plans to host a conference call to review the AL001 Phase 2 results on July 29 at 1:00 p.m. ET.

Alector will also present two posters related to its AL002 Alzheimer's disease (AD) program. The first poster will include the results of the AL002 Phase 1 study in healthy volunteers and the second poster will highlight the study design of the ongoing INVOKE-2 trial in people with early AD.

Oral Presentation for AL001 Phase 2 Data

Presentation Title Six Months Interim Analysis of the Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (#54593)

Session Name Human: A potpourri of human clinical trials

Presenter Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector

Session Date and Time Thursday, July 29, 2021 at 10 a.m. ET

Poster Presentations for AL002

Poster presentations will be available for on-demand viewing beginning on Monday, July 26.

Poster Title INVOKE-2 -- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer's Disease (#54615)

Presenting Author Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector

Poster Title A Phase 1 Study of AL002 in Healthy Volunteers (#54669)

Presenting Author Mike Ward, Ph.D., Senior Director, Clinical Science, Alector